Clinical-stage psychedelics drug development company Filament Health Corp. FLHLF has obtained two new patents for the extraction and standardization of natural psilocybin and associated psychedelic compounds by the USPTO.
Filament’s proprietary technology to extract and standardize stable doses of natural compounds from magic mushrooms received the first-ever patent on August 3, 2021, and built on other three patents by the USPTO and five by the Canadian IP Office.
The two new patents, which describe technology for transforming variable psychedelic raw materials into pharmaceutical-grade drug candidates, add to the company’s IP portfolio which now consists of ten patents for extracting and standardizing methods of natural psychedelics.
Filament’s IP director Taran Grey said that when the company was founded it was thought that producing stable psilocin was impossible.
“We have since been granted patent protection for successful production of psilocin at all stages of manufacture: from extraction to purification to standardization and beyond,” Grey stated, exemplifying with Filament’s issued patents around noningestive administration.
“The fact that we have never had a patent application denied, compared to the industry average of a less than 50% success rate, is further validation of this talent," he said.
Photo courtesy of Susie Hedberg and only_kim on Shutterstock.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.